

Farxiga[®] (dapagliflozin) – First-time authorized brand alternative

- On January 3, 2024, [Prasco launched](#) an authorized brand alternative of Astra Zeneca's [Farxiga \(dapagliflozin\)](#) tablets.
- Farxiga is approved for the following:
 - To reduce the risk of sustained estimated glomerular filtration rate decline, end-stage kidney disease, cardiovascular (CV) death, and hospitalization for heart failure in adults with chronic kidney disease at risk of progression
 - To reduce the risk of CV death, hospitalization for heart failure, and urgent heart failure visit in adults with heart failure
 - To reduce the risk of hospitalization for heart failure in adults with type 2 diabetes mellitus (T2DM) and either established CV disease or multiple CV risk factors
 - As an adjunct to diet and exercise to improve glycemic control in adults with T2DM.